Health ProductsDear Healthcare Professional Letter

XIGRIS [drotrecogin alfa (activated)] - Worldwide Withdrawal - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Biologic/vaccine
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Eli Lilly Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories



Health Canada Endorsed Important New Benefit-Risk Information for XIGRIS [drotrecogin alfa (activated)]

October 28, 2011

Subject: Worldwide Withdrawal of XIGRIS® [drotrecogin alfa (activated)]

Dear Health Care Professional,

Eli Lilly and Company is undertaking a worldwide withdrawal of Xigris® [drotrecogin alfa (activated)] due to new clinical trial findings of lack of efficacy which calls into question the benefit-risk profile of the product.

The withdrawal is effective immediately and will be completed as expeditiously as possible.

  • Xigris treatment should not be initiated for new patients. Patients currently receiving treatment with Xigris should have their Xigris treatment discontinued.
  • This action is based on results from the PROWESS-SHOCK trial which showed no 28-day survival benefit of Xigris in septic shock patients.
  • The lack of efficacy seen in this trial calls into question the benefit-risk profile of Xigris for the indicated patient population.

Xigris was originally authorized in 2003 in Canada for treatment of severe sepsis based on the results of the PROWESS study, in which Xigris showed significant improvement in 28-day all-cause mortality. The PROWESS-SHOCK study showed a 26.4% 28-day mortality rate in patients receiving Xigris versus 24.2% in those who did not (RR 1.09 [0.92, 1.28]). The reasons for the unexpected results in PROWESS-SHOCK are not known; however, a contributing factor may be advances achieved in the standard of care for patients with sepsis and septic shock in the 10 years since completion of the original PROWESS trial. This is suggested by the fact that the mortality rate in placebo-treated patients in PROWESS-SHOCK was considerably lower than predicted.

Check your inventory for Xigris. All strengths and package sizes are subject to this withdrawal. If Xigris is found, return the product to the supplier (wholesaler/distributor) from whom it was purchased. Your supplier will return the product to Eli Lilly Canada Inc. For any additional questions about Xigris, please contact the Lilly Canada Customer Response Centre at 1-888-545-5972.

This Dear Health Professional Letter (DHPL) is also posted on Advisories, Warnings and Recalls and on Eli Lilly Canada.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments.

Eli Lilly Canada Inc.
Toronto, Ontario
1-888-545-5972

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

  • Report online at MedEffect Canada
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa, Ontario K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738

To change your mailing address or fax number, contact the Market Authorization Holder (Industry).

Sincerely,

original signed by

Loren D. Grossman, MD, FRCPC, FACP
Vice-President, Research and Development
Eli Lilly Canada Inc.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime